Form 4: 4D Molecular Therapeutics: Officer Acquires Stock Options
SEC Form 4
Fariborz Kamal, President & COO of 4D Molecular Therapeutics, acquired stock options for 178,400 shares on March 6, 2025.
Summary
- On March 6, 2025, Fariborz Kamal, the President & COO of 4D Molecular Therapeutics, acquired stock options for 178,400 shares.
- The options have an exercise price of $4.14.
- The options vest monthly, starting March 6, 2025, over a four-year period.
- The options expire on March 5, 2035.
Sentiment
Score: 5
Explanation: This is a routine filing related to stock option grants, so the sentiment is neutral.
Industry Context
This is a standard Form 4 filing, indicating a change in beneficial ownership by a company insider. Such filings are common and provide transparency into executive compensation and stock ownership.
Stakeholder Impact
- The granting of stock options aligns the executive's interests with those of the shareholders, incentivizing them to increase the company's value.
Key Dates
| Date | Description |
|---|---|
| 03/06/2025 | Date of earliest transaction: Fariborz Kamal acquired stock options. |
| 03/06/2025 | Vesting Commencement Date: Options vest monthly from this date. |
| 03/05/2035 | Expiration Date: Stock options expire. |
| 03/10/2025 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.